Role of the Immune System in Preventing Laryngeal Cancer
ConditionHead & Neck Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-99
SponsorEuropean Institute of Oncology
About this trial
Laryngeal dysplasia and progression to carcinoma: investigating genetic and immune alterations predictive of malignant transformation
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Histopathological diagnosis of laryngeal dysplasia.
Age >18 years and informed consent.
Disqualifiers
Prior surgical, radiotherapeutic, or oncologic treatments for head and neck regions.
Congenital or acquired immunodeficiency disorders.
Synchronous malignancies.
Immunosuppressive therapy.
Trial population
The study will recruit 150 consecutive, untreated LDy patients, potentially within a multicenter framework.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
differences in TILs counts
detection of differences in TILs counts from Laryngeal dysplasia to progression to carcinoma
Time frame
2 yearsSecondary outcomes
1
Differences in TILs counts in LDy lesions
Detection of Differences in TILs counts in LDy lesions categorized by their risk of malignant progression
Time frame
2 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov